Cidofovir (CDV) is a FDA-approved nucleoside analog used to treat severe human cytomegalovirus (HCMV) infection. Until now, no clear antineoplastic effects of CDV have been reported outside of the setting of viral infection, and no prior evidence has shown a role for CDV as an antineoplastic agent for glioblastoma (GBM). Our pre-clinical evaluation of CDV revealed its potent antitumor activity against GBM, independently of the status of HCMV infection. CDV is incorporated into tumor cell DNA, thereby promoting double-stranded DNA breaks and triggering downstream apoptotic signaling. In-vivo data with human GBM intracranial xenografts showed that, when treatment with CDV was combined with radiation therapy, it significantly increased the survival of tumor-bearing mice. We believe that this finding may represent a new therapeutic avenue for GBM treatment. Results: CDV possesses potent antineoplastic activity against HCMV infected GBM cells. This activity is associated with inhibition of HCMV gene expression and with activation of cellular apoptosis. Surprisingly, we also determined that CDV induces GBM cell death in the absence of HCMV infection. CDV is incorporated into tumor cell DNA, which promotes doublestranded DNA breaks and induces apoptosis. In the setting of ionizing radiation treatment (RT), the standard of care for GBM in humans, CDV augments radiation-induced DNA damage and further promotes tumor cell death. Combined CDV and RT treatment significantly extended the survival of mice bearing intracranial GBM tumors.
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Introduction
Glioblastoma (GBM) is the most common primary brain tumor in adults, and despite advances in our understanding of GBM biology, and the use of these molecular insights to test innovative approaches for treating GBM, mean GBM patient survival remains 12-15 months (1).
We hypothesized that persistent viral infection plays a role in GBM pathogenesis, given the extensive results from our laboratory and others demonstrating that human cytomegalovirus (HCMV) infection is present in a majority of human GBMs (2) . Several HCMV gene products that are expressed in human GBMs are thought to contribute to tumor pathogenesis, including the expression of HCMV IE1 protein which has been associated with length of patient survival (3) (4) (5) (6) (7) . Furthermore, improved survival was recently reported for patients with GBM who were treated with the oral antiviral drug valganciclovir, when used in combination with standard of care treatment for this cancer, radiation and temozolomide, suggesting that anti-HCMV therapy might provide clinical benefit to GBM patients (8) .
To determine whether inhibition of HCMV gene expression impacts the biology of GBM, we used the antiviral agent cidofovir (CDV), an acyclic nucleoside phosphonate analog with a broad spectrum anti-viral DNA synthesis activity that has been approved for the treatment of CMV retinitis in patients with AIDS (9, 10) . CDV has also proved effective for the treatment of other DNA viral related diseases including the central nervous system disease progressive multifocal leukoencephalophathy (PML) (11) . The antiviral activity of CDV is thought to result 5 limitation of using high doses of CDV in up to 15% patients (14) , new lipophilic CDV derivatives administered orally causing minimum toxicity are already being tested (15) .
In the setting of virus-driven oncogenesis, CDV has been shown to inhibit cancer growth in various in vivo models, including those involving human tumor xenografts (Epstein-Barr virus-associated nasopharyngeal carcinoma and human papillomavirus-induced cervical carcinoma) and polyomavirus-induced rodent tumors (hemangiomas in rats as well as hemangiosarcoma development in mice) (16) (17) (18) (19) (20) . In addition, hemangioma tumors are inhibited by CDV, independent of viral infection, by induction of endothelial cell apoptosis (13, 21) . This effect was associated with S-phase arrest, PARP activation, p53 up-regulation, and caspase activation (22) . The latter study results therefore suggest that CDV can inhibit cellular DNA synthesis and inhibit tumor cell proliferation independent of endogenous viral presence, potentially by incorporation into cellular DNA as a substitute for dCTP, as demonstrated in the case of HPV-infected human keratinocytes (23) .
While most cytosine nucleoside analogs (e.g., ara-C and gemcitabine) block tumor growth by inducing DNA chain termination, CDV appears to act by inhibiting secondary rounds of DNA synthesis (24, 25) . Because of this, CDV may have unique potential as a radiationsensitizing agent (26, 27) . CDVpp incorporation into radiation damaged DNA may activate tumor cell apoptotic response mechanisms. Indeed the literature supports a "radio-sensitiser" role for CDV in the setting of ionizing radiation (28) .
In order to determine whether CDV inhibits GBM cell growth, as well as to address viral dependency of observed anti-tumor effects, we conducted experiments to evaluate CDV effects on GBM cell lines and primary explant cultures, both in the presence or absence of HCMV infection. To determine how growth-inhibitory effects of CDV interact with ionizing radiation 6 therapy (RT), we extended our experiments to include in vivo analysis of combined CDV + RT treatment, using orthotopic GBM xenograft models. Our data indicate a previously unrecognized potent anti-glioma effect of CDV, which acts in combination with RT for increased tumor cell kill through increased apoptotic response.
Materials and Methods
Primary GBM samples and neurosphere growth assays
Tissue samples were obtained during surgery from patients diagnosed with GBM using an IRB-approved protocol. Fresh tumor tissues were subjected to enzymatic digest, mechanically dissociated, and cultured as neurospheres as previously described by our group (29) . For growth assays, cells were cultured in neurosphere media (Neural Basal Media + EGF/FGF2) at 1000 cells/well in 96-well plates. Media was replaced every other day, with or without CDV (100 μM, where indicated) and tumor cells monitored using an inverted microscope fitted with a camera. 96-120 hours following initial culturing, spheres were photographed and counted. All sample incubations were in quadruplicate. Experiments were repeated twice for each primary culture 
GBM xenografts
U87MG cells were cultured as described above. Human GBM primary tissue SF7796 was 
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established and maintained as serially passaged subcutaneous xenografts in athymic mice. Both U87MG and SF7796 were modified by lentiviral infection for stable expression of firefly luciferase to enable in vivo bioluminescence imaging, as previously described (30) . To prepare tumor cells from subcutaneous xenografts for intracranial injection, previously described protocols were used (31) . Both SF7796 and U87MG cells were resuspended in DMEM at 1 x 10 8 cells/mL.
Intracranial tumor establishment in athymic mice
Five to six-week-old female athymic mice (nu/nu, homozygous: Simonsen laboratories, Gilroy, CA) were housed under aseptic conditions, and received intracerebral tumor cell injection as previously described (31) . Briefly, mice were injected with 300,000 cells (3 μl) into the right striatum using 26-gauge needle. Animals were monitored daily and imaged 1-2 x weekly until euthanized when exhibiting significant neurological deficit, or greater than 15% reduction from their initial body weight. The number of animals consisted of 8-10 for each treatment group. CDV treatments were by intraperitoneal injection (100 mg/kg), 3x/week until required euthanasia, as indicated by animal subject body condition. The vehicle used was sterile saline.
Bioluminescence monitoring of intracerebral tumor growth
In preparation for bioluminescence imaging (BLI), mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), then administered 150 mg/kg of luciferin (D-luciferin potassium salt, Gold Biotechnology, MO) via intraperitoneal injection. Ten minutes after luciferin injection, mice were examined for tumor bioluminescence using an IVIS Lumina (31, 32) .
Mouse irradiation
Mice were anesthetized via inhalation of 2.5% isoflurane with 1 liter of oxygen per minute 
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using the unpaired Student's t-test. All data are presented as a mean ± SD. We considered P values of less than 0.05 as statistically significant.
Results
To investigate whether CDV inhibits HCMV-infected GBM tumor cell growth, we treated primary patient-derived GBM cells (passage zero) with CDV (20 μM) for 72 hrs following initial establishment of neurosphere cultures. Cells treated with CDV ( Figure 1A -B) displayed phenotypic changes suggestive of cell apoptosis. To investigate the mechanism underlying this response, we used an apoptosis antibody array to profile cell lysates from control and CDV-treated samples, with results indicating at least two apoptotic pathways being activated in the presence of CDV: p53 and Fas/TNFa-Trail ( Figure 1C) . Results from the antibody array were quantified ( Figure 1D ) and validated using western blot analysis ( Figure 1E ). Furthermore, the expression of HCMV genes (e.g., UL44) in this GBM sample was inhibited by CDV treatment ( Figure 1E ). We similarly examined the CD133+ (stem-like) cellular fraction from another GBM sample, which was also positive for endogenous HCMV. CDV treatment inhibited tumor sphere formation for these CD133+ cells (Fig 1B, white bars) as well as the expression levels of various viral genes (e.g., pp71) and cellular proteins that are important contributors to GBM pathogenesis (e.g., Sox2, SCF). These latter data (Supplementary Figure S1 ) suggest that the use of antiviral drug CDV inhibits the expansion of primary GBM spheres by multiple mechanisms, including the activation of pro-apoptotic pathways, and the inhibition of selfrenewal and mitogenic pathways. Interestingly, when the fibroblasts were grown at confluence (no mitoses due to contact inhibition), the EC50 was dramatically increased (Supplementary Figure S5A) .
Since CDV is a nucleoside analog, we hypothesized that it might induce apoptosis by becoming incorporated into cellular DNA, leading to DNA injury and subsequent activation of programmed cell death. Further, we hypothesized that the combination of CDV with ionizing radiation (RT), which is the standard of care for GBM, might act in concert to promote further tumor cell apoptosis. To test these hypotheses, we examined proliferating U87MG incorporation nucleotide per DNA base pair in both "CDV only" and "CDV + RT" -treated cultures. Analysis of additional time points revealed that the extent of CDV incorporation was time-dependant, but was not significantly affected by RT treatment (Supplementary Figure S5B) .
To test the effects of CDV on normal cells, MRC-5 fibroblasts were exposed to the same doses of 14 C-labeled CDV as U87MG (without irradiation). The results showed that the GBM cell line incorporates the drug into DNA at a much higher rate ( Figure 2C ) than MRC-5. In addition, when cellular divisions were halted by contact inhibition, the incorporation was minimal. This would indicate that CDV treatment primarily affect rapidly dividing cells.
To test the hypothesis that CDV causes cellular DNA damage, and that the combination of CDV plus RT promotes more robust DNA damage than either agent alone, we performed Western blot analysis with antibodies specific to proteins involved in DNA repair, using cell lysates from U87MG cells exposed to CDV, irradiation, or the two in combination. Analysis of cellular phospho-histone H2A.X, a sensitive indicator of double-stranded DNA breaks (33), showed that both CDV and RT induce H2A.X phosphorylation. This effect was dramatically enhanced when CDV was combined with RT (27.6-or 21-fold increase when compared to treatment with only radiation or CDV, respectively) ( Figure 2D ). Interestingly, when normal fibroblasts were treated with CDV, no induction of H2A.X phosphorylation was observed ( Figure 2E and 2F) . However, when fibroblasts were previously infected with HCMV, exposure to CDV caused significant upregulation of activated H2A.X (sensitizing effect). HCMV showing that virus-associated subcutaneous xenograft tumors responded to CDV treatment (13, 17) , mice administered with 100 mg/kg CDV, 3 times weekly, either delayed or prevented intracranial tumor development, compared to mice treated with vehicle only (Figures 3A, 3B ).
Importantly, CDV treatment significantly extended animal subject survival for each of the two xenograft models we tested ( Figures 3C, 3D) . 
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S6) showed that combined treatment significantly extended survival compared to either monotherapy ( Figure 6C and 6D) . Therefore, based on the results of two distinct intracranial xenograft models, we conclude that combination CDV + RT treatment has the most substantial anti-tumor effect.
Discussion
Here we show for the first time that CDV, an FDA approved drug for treatment of for its conversion to the active metabolite that is incorporated into viral DNA as a chain terminator (36) . In contrast, CDV does not depend upon a viral gene product to become phosphorylated, but rather is phosphorylated by the human cellular cytidine kinase enzyme.
Thus, there is no virus-specific activity required for conversion of CDV to an active state. An important issue is the safety of CDV treatment to normal cells of a patient. Our data strongly suggest that CDV primarily affect rapidly dividing cells, sparing cells that replicate their DNA at a lower rate. The incorporation of CDV molecules into newly synthesized DNA is therefore dependant on the mitotic rate (23) . No apoptotic cells were detected outside the tumor tissue of treated mice and normal fibroblasts grown in contact inhibition did not incorporate toxic levels of CDV.
The current literature suggests that, as opposed to other cytosine analog antineoplastic agents such as gemcitodine, CDV does not cause direct DNA chain termination upon incorporation into cellular DNA, but likely promotes stalling of the DNA replication fork (37) .
DNA fork stalling could lead to "futile cycling" of the replication fork or of DNA double strand break repair. In either case, if the DNA replication process is not sustained, affected cells may undergo programmed cell death.
By the addition of further DNA insult, such as ionizing radiation, we hypothesized that cellular apoptotic response would increase. In vitro data revealed a dramatic increase (over 21-fold) of a phosphorylated histone H2AX indicating DNA injury/instability after exposure to both CDV and ionizing radiation, and that this effect resulted in reduced tumor growth in vivo, which, in turn, results in extending animal subject survival. 
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recently shown (44) . Studies with analogs of CDV having more favorable pharmacokinetics are underway. 
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